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Surveillance of the antiviral susceptibil-
ity of influenza viruses in Europe revealed
the emergence of influenza A(H1N1)
viruses naturally resistant to the anti-
neuraminidase inhibitor oseltamivir (Ta-
miflu) [1]. Currently, resistant viruses are
most prevalent in Europe (25%) but less
prevalent in the Americas (16%) or the
Western Pacific region (4%) [2]. In
Europe, the prevalence varies between
countries, with highest levels in Norway
(66.5%) and France (46.6%) [3]. These
frequencies are in sharp contrast with
those observed for H1N1 viruses during
previous seasons (0 to ,1%) [4–8].
Resistance was linked to the H275Y
mutation (H274Y in N2 numbering) of the
N1 known to confer high level resistance
to oseltamivir but not to the other anti-
neuraminidase inhibitor, zanamivir (Re-
lenza) [9–12]. Resistant H1N1 viruses
with the H275Y change have been
isolated from patients treated with oselta-
mivir and more frequently in children,
especially in Japan, the country with the
highest per capita usage of oseltamivir
[10,13]. The current frequencies of resis-
tant H1N1 viruses are not correlated with
oseltamivir usage, which suggests that
selective drug pressure has not been
associated with continued transmission,
although it may have been involved in
their initial emergence. Clinical H1N1
isolates with the H275Y mutation were
previously found to be generally less fit in
terms of replication, infectivity for mice or
ferrets, or transmission potential [14,15],
although the mutation had a less pro-
nounced and variable effect on virus
fitness for laboratory strains such as
WSN or PR8 viruses or for H5N1 viruses
[9,16–18]. To understand the molecular
basis of the apparent fitness of the resistant
H1N1 viruses that emerged during the
2007–2008, season we determined the
enzymatic characteristics of their neur-
aminidase.
A selection of H1N1 viruses isolated by
the National Influenza Center (Northern-
France) from specimens received in the
frame of routine surveillance through the
GROG sentinel network between weeks
35/2007 and 03/2008 (Table 1) were
studied. Using a standard neuraminidase
inhibition assay, the IC50 values for
oseltamivir ranged from 1.3 to 5.9 nM
for sensitive viruses and were much higher
(IC50, 624 to 942 nM) for resistant viruses
(Table 1), as previously published
[9,10,12,19]. All viruses were sensitive to
zanamivir (IC50, 1.2 to 3.0 nM). All
resistant viruses harbored the H275Y
substitution in their N1.
Kinetic analyses of sialidase activities of
the neuraminidase were performed using
the MUNANA fluorogenic substrate in the
absence or presence of neuraminidase
inhibitors on whole virus suspensions as
described [20]. The Michaelis-Menten
constant (Km), which reflects the affinity
for the substrate, and the Vm, which
reflects the activity of the enzyme, were
determined (Table 1). The Km values for
the MUNANA substrate of most viruses
from the 2007–2008 season sensitive to
oseltamivir (9.061.2 mM) were significant-
ly reduced as compared to those measured
for the A/New Caledonia/20/99(H1N1)
(NC99) and A/Solomon Islands/3/
2006(H1N1) (SI06) vaccine strains and
for sensitive H1N1 isolates from previous
seasons (28.062.7 mM). One virus
(#0006/07) showed an intermediate Km
(12.460.6 mM). The mean Km values for
MUNANA (19.462.9 mM) were signifi-
cantly (p,0.001) higher for viruses resis-
tant to oseltamivir as compared to sensi-
tive viruses, as previously reported [11,20].
However, Km values (19.462.9 mM) for
resistant viruses from the 2007–2008
season remained below the Km values
(28.062.7 mM; p,0.01) for NC99 and
SI06 vaccine strains and sensitive H1N1
isolates from previous seasons. Analysis of
the Vm values showed no significant
difference for sensitive as compared to
resistant viruses from the 2007–2008
season (3.160.75 and 3.461.52 U/sec,
respectively). However, the N1 of viruses
circulating prior to 2007–2008 exhibited
significantly lower Vm values (1.260.47
U/sec; p,0.05) than that of viruses from
the 2007–2008 season except for isolate
#0006/07, which had a low Vm value
(0.63 U/sec).
Inhibition constants (Ki) for oseltamivir
and zanamivir were also determined
(Table 1). As for the Km values, Ki values
for zanamivir and oseltamivir were signif-
icantly and about 2-fold lower for the
2007–2008 viruses sensitive to oseltamivir
(except for isolate #0006/07) as compared
to NC99 and SI06 vaccine strains and
sensitive H1N1 isolates from previous
seasons. As expected, for the 2007–2008
viruses resistant to oseltamivir, mean Ki
values for oseltamivir were more than 500-
fold higher than for their sensitive coun-
terparts (58611 and 0.1360.07 nM;
p,0.001), albeit reduced about 2-fold
when compared to values previously
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200 nM; [11,15,20]). Thus, the neuramin-
idase of H1N1 viruses from the 2007–2008
season exhibits an increased affinity for the
substrate as well as for the two anti-
neuraminidase inhibitors and a higher
activity as compared to previously circulat-
ing viruses suchasNC99 orSI06,exceptfor
isolate #0006/07, which behaved as an
intermediate. As a result, theneuraminidase
from recent resistant viruses that harbor the
H275Y substitution has a slightly higher
activity and affinity for the substrate than
that from previously circulating sensitive
viruses. These features may contribute to
their overall fitness and ability to be
transmitted, although the contribution from
other genes cannot be excluded at present.
When comparing the growth character-
istics in vitro on MDCK SIAT-1 cells of
the resistant viruses with that of sensitive
viruses from the 2007–2008 season or
from previous seasons, no significant
differences in growth kinetics or final virus
titers were observed (Figure 1). These
results indicated that, at least in vitro, the
presence of the H275Y mutation did not
significantly impair the fitness of the
viruses, unlike what had been previously
reported in the case of the A/Texas/36/
91 virus on MDCK cells [15]. Whether
the same holds true in vivo remains to be
determined.
Phylogenetic analysis of the N1 se-
quences showed that sensitive and resistant
viruses from the 2007–2008 season belong
to the same clade, including two viruses
from Hawaii (A/Hawaii/21/2007 and A/
Hawaii/28/2007) with the H275Y change
(Figure 1). Strikingly, isolate #0006/07
(A/Paris/6/2007), which behaved as an
intermediate, belonged to a different
clade. When analyzing the H1 sequences,
again resistant and sensitive viruses be-
longed to the same clade, including the
recent vaccine strain A/Brisbane/59/
2007 (Figure 2). No specific amino acid
changes that could be compensating for
the presence of the H275Y substitution in
the N1 were found in the H1 of resistant
viruses. For instance, sensitive (#0497/07,
#1149/08) and resistant (#0644/07 and
#1170/08) viruses with the same HA and
NA (except for the H275Y and G354D
changes) amino acid sequences represent-
ing the consensus sequences of the recent
H1N1 viruses had similar growth charac-
teristics, similar Vm values for their N1,
and differed in their Km and Ki values
based solely on the two changes in the N1.
In addition to the H275Y change, most,
but not all, resistant viruses were charac-
terized by the presence of a G354 as for
the NC99 and SI06 viruses, whereas a
D354 was found for sensitive viruses
(Table 1). According to the three-dimen-
sional structure of the N1 of an H5N1
avian influenza virus [21], residue 354 is
located on the top external side of the
neuraminidase tetramer at a distance from
the catalytic site and subunit interfaces. It
is therefore not likely to be compensating
for the H275Y substitution. Indeed, as
shown for isolate #0963/08 as compared
to other resistant isolates, the presence of a
D354 rather than a G354 does not have a
major impact on the enzymatic character-
istics of the N1 (Table 1). Substitutions
that distinguish the majority of H1N1
viruses from the 2007–2008 season from
both NC99 and SI06 are H45N, K78E,
E214G, R222Q, G249K, T287I, K329E,
and D344N. Two of these positions are
located in the stalk region (45 and 78), and
three (222, 249, 344) in the vicinity of the
catalytic site according to the three-
dimensional structure of the N1 [21].
Substitutions in the vicinity of the sub-
Figure 1. Growth Kinetics of H1N1 Viruses from the 2007–2008 Season Sensitive or
Resistant to Oseltamivir. Two sensitive (A/Paris/497/2007 and A/Paris/1149/2008) and two
resistant (A/Paris/644/2007 and A/Paris/1170/2008) viruses from the 2007–2008 influenza season,
as well as the reference strain A/Solomon Islands/3/2006 and an isolate from the 2003–2004
season (A/Paris/650/2004), were amplified and titrated on MDCK cells. The indicated viruses were
then used to infect MDCK SIAT-1 cells [31] at an m.o.i. of 0.001 and incubated for 72 hours at 35uC
in the presence of 1 mg/ml TPCK trypsin. At the indicated time points, the supernatants were
harvested and virus titers were determined by plaque assays on MDCK cells.
doi:10.1371/journal.ppat.1000103.g001
Table 2. GenBank Accession Numbers
Virus Isolate H1 N1
A/Paris/0650/2004 EU685784 EU718491
A/Caen/1670/2006 EU551852 EU551817
A/Caen/1951/2006 EU551843 EU551819
A/Paris/2149/2006 EU551844 EU551829
A/Paris/2207/2006 EU551853 EU551816
A/Paris/0692/2007 EU551850 EU551827
A/Paris/0006/2007 EU551851 EU551807
A/Paris/0194/2007 EU551848 EU551808
A/Paris/0286/2007 EU551838 EU551828
A/Paris/0341/2007 EU551832 EU551811
A/Paris/0438/2007 EU551849 EU551830
A/Paris/0497/2007 EU551839 EU551818
A/Paris/0546/2007 EU551837 EU551822
A/Paris/0577/2007 EU551835 EU551815
A/Paris/0611/2007 EU551847 EU551823
A/Paris/0644/2007 EU551833 EU551809
A/Paris/0658/2007 EU551845 EU551820
A/Paris/0749/2007 EU551831 EU551826
A/Paris/0814/2007 EU551840 EU551825
A/Paris/0847/2007 EU551834 EU551824
A/Paris/0910/2008 EU551836 EU551810
A/Paris/0963/2008 ND EU551821
A/Paris/0974/2008 EU551841 ND
A/Paris/1149/2008 EU685786 EU685787
A/Paris/1154/2008 EU551842 EU551812
A/Paris/1157/2008 ND EU551814
A/Paris/1170/2008 EU685785 EU685788
A/Paris/1208/2008 EU551846 EU551813
ND, not determined.
doi:10.1371/journal.ppat.1000103.t002
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affinity of the neuraminidase for its sub-
strate, whereas remote substitutions in the
ectodomain are less likely to be significant.
Indeed, sensitive (#0611/07) and resistant
(#1157/08) viruses with E214 showed
similar Km and Ki values as their counter-
parts with G214 (Table 1). According to the
N1 sequences available for H1N1 viruses in
the ISD database [22], the specific amino
acid combination mentioned above
emerged in 2007. In particular, a K249
had not been observed previously, and its
prevalence increased to reach approximate-
ly 85% for 2008 isolates in the database
(100% for isolates from Northern-France).
Isolate #0006/07, which lacked the
G249K change, showed intermediate Km
and Ki values. Some viruses, such as A/
Missouri/13/2006 and A/California/10/
2006, were reported to have an R249 in
association with the specific combination of
amino acids, except for the K78E and
D344N changes. It would be of interest to
determine their Km and Ki values.
Overall, our results suggest that a specific
combination of amino acids may have
resulted in an increased affinity of the N1
of recent H1N1 viruses for its substrate and
neuraminidase inhibitors. It will be of
interest to determine more precisely which
exact changes are involved through muta-
genesis using the previously described
transient N1 expression system for kinetic
analyses of the neuraminidase activity [20].
Appropriate functional balance between
the activities of the two influenza virus
glycoproteins towards sialic acids, i.e.,
receptor binding (hemagglutinin) and sia-
lidase activity (neuraminidase), is essential
for virus fitness [23]. The H1 of viruses
from the 2007–2008 season differ from
both NC99 and SI06 by three substitu-
tions (D35N, R188K, E273K), none of
which are involved in direct interactions
with the receptor and therefore not likely
to result in changes of affinity of the H1 for
the receptor. According to this hypothesis,
which warrants further experiments, the
increased affinity of the N1 of 2007–2008
viruses for its substrate would not have
been compensated by an increased affinity
of the H1 for the receptor. Therefore,
viruses with a Y275 that have only a
slightly higher affinity for the substrate as
compared to H1N1 viruses that circulated
previously may have a more appropriate
balance of their hemagglutinin and neur-
aminidase activities than viruses with a
H275 that have a 3-fold increased affinity
of their neuraminidase for the substrate.
As a result, as for influenza A viruses
resistant to adamantanes [24–28], the
Figure 2. Phylogenetic Relationships of the H1 and N1 Genes. The phylogenetic analysis was performed on the alignment of sequences from
nucleotides 87 to 995 (H1) or 90 to 1286 (N1) (numbering from ATG). The dendrogram was constructed by genetic distance matrix and calculated
with the DNADIST program using the Kimura-2 parameters model with transition-to-transversion ratio of 2.0 and neighbor-joining analysis in the
PHYLIP package [32,33]. Sequences from the H1 or the N1 from A/NewCaledonia/20/99 were used as outgroup. Bootstrap values of 1,000 replicas are
given as percentages at the nodes. Isolates from Northern-France from the 2006–2007 season are in italics. Viruses with a Y275 in the neuraminidase
sequence are shown in bold and vaccine strains in capitals. Published sequences were issued from the influenza sequence database at Los Alamos
National Laboratory [22].
doi:10.1371/journal.ppat.1000103.g002
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outcompeted upon circulation in the
community. It should be emphasized,
however, that the relative fitness and
ability to be transmitted of the resistant
versus sensitive viruses may be modulated
by characteristics of other genes. This will
require whole genome sequencing. The
circulation of H1N1 viruses naturally
resistant to oseltamivir underlines the fact
that genetic variations may result in
variations in sensitivity to oseltamivir in
the absence of selective drug pressure, as
shown for H5N1 viruses [20,29]. Genetic
variations of the hemagglutinin and neur-
aminidase are mainly driven by the
immune response, and adventitious prop-
erties that result in changes in fitness may
be co-selected. Such a phenomenon could
potentially take place for H5N1 viruses
and also for H3N2 viruses. Genetic
variations like these emphasize the need
to carefully monitor the affinity of the
neuraminidase for its substrate and anti-
neuraminidase inhibitors in relation with
the binding affinity of the hemagglutinin
for its receptor for influenza viruses
circulating in the population, as well as
for avian influenza viruses with pandemic
potential.
Sequence Accession Numbers
GenBank accession numbers are listed
in Table 2 for the viruses included in this
report.
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